# New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients

> **Open Intelligence Dossier** · First detected: 2026-10-31 03:00 UTC · Category: Health

## Executive Summary
An experimental mRNA vaccine targeting KRAS mutations triggered immune responses in 99% of pancreatic cancer patients in recent Phase 2 study results.

## Intelligence Brief
A new experimental vaccine targeting rogue genes linked to 90 percent of pancreatic cancers has demonstrated the ability to trigger immune responses in 99 percent of patients. According to coverage from Oncodaily and ScienceAlert, Cosimo Commisso reported that this personalized KRAS vaccine generated these significant immune responses. The vaccine utilizes mRNA technology to harness the power of the immune system. While the response rate was high, Inkorr reports that the vaccine triggered strong T-cell responses in nearly all patients but failed to delay relapse. The treatment specifically targets KRAS mutations, which are common drivers in the development of pancreatic tumors.


Multiple outlets are tracking the development and presentation of this data. GlobeNewswire and Yahoo Finance UK report that Elicio Therapeutics is scheduled to present results from the Phase 2 AMPLIFY-7P trial at the SITC 2026 Annual Meeting. Investing.com further confirms that Elicio will present KRAS vaccine data at this cancer conference. Additionally, Health and Me and IFLScience have emphasized the vaccine&#039;s ability to target the specific genetic mutations linked to the vast majority of these cancer cases, while Medical Xpress notes the investigational nature of the study regarding KRAS mutations.


Contextual reports from Nature and AllSci provide insight into the broader scientific landscape of these treatments. Nature describes the design of a tumor landscape-modifying vaccine that utilizes a unique TLR2/6 agonist for refractory pancreatic cancer. Meanwhile, a team from Yonsei has shown that a dual-antigen KRAS/WNT5a vaccine can enhance pancreatic cancer immunotherapy. These developments are part of a wider trend in mRNA vaccine application, as highlighted by NPR, which is exploring what the latest advancements in mRNA technology mean for the future of cancer treatment and personalized medicine.


Future developments center on the official presentation of the AMPLIFY-7P Phase 2 results at the upcoming SITC 2026 Annual Meeting. Observers and medical professionals will be looking for more detailed data from Elicio Therapeutics to understand why the strong T-cell responses reported by Inkorr did not translate into a delay in patient relapse. Further research into dual-antigen vaccines, such as the KRAS/WNT5a approach mentioned by AllSci, may also provide a path forward for enhancing the efficacy of these immunotherapies in treating refractory pancreatic cancer cases.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| IFLScience | A New Experimental Vaccine Targets Rogue Genes Linked To 90 Percent Of Pancreatic Cancers | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxQNzlMRXFTb3RFTGktUVVRUDJta3hUazBXWGpFMm01MlNyTGFGTmN4VWRrZHVZQWYxdzBYNDkwcFktVHZMQUw2M1JkN2dlYmFuZmd5TTliZlJuTTd5ZGJhVEFJQmxKV2tQZm10SVdja0JIZ3BodVl4VFlwUnZ5Z1ZEU2tJcW5ud3ZjTVZEZjZ5c3hXd2pJeXRleFJfM3ByN2h2QkphSlJaM216bjRiZHVGSThBMFAyaHJqZ3VFWktFcw?oc=5) |
| Inkorr | Pancreatic Cancer Vaccine Triggers Strong T-Cell Response in Nearly All Patients but Fails to Delay Relapse | [Source Link](https://news.google.com/rss/articles/CBMi4wFBVV95cUxOYzA0Tkl4LVAzYnUtYll2dmh2b09kXzYtTXItaGRYeEZDSkVDbV9nVUV1dVVzZWxVRFJua2RzU0FleWlLZjBhVlYxZEpGa2NvakhJc085cUVzZVBqRVpucjNlV1YwN09Gc3FwQnBMRlRqQTFCVy1hV2k3dGtBME43bUF0TG03dVB1MmxRZTFvY2JwYXhEOHVqanVmekZrUU5MZ2lNR0VoMjAzbUVDUkVpLXh5X0duV09YTGRUTkI2UnN4VTNzckpPTWxrMmNvZy05cGM0R3dzU2p5ZUxiaE9wT3p2VdIB6AFBVV95cUxPaUozVmZQRm41VEhQeEFfSTJrTVNFekJQOGZYSC1JdndPejRUSjAyUVhxd05mdjNycjVxbUJtdlhZbnNUOGl1WUNQWnZjM214UjFqMnRrNVU5RkdiV1RwMjRJMFpYUFRPeml3eEV2RTJ) |
| NPR | What the latest on mRNA vaccines means for cancer | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxOT0ZwMGVSQ2tscEpfYnFTZ3hUZkR2SEg3My14enROc3pRMEJNQUdoMFNpdUNpTi1lUzJyb0tLNC1FbktuMnU4QUdEUFZzSDREVVdXMFM4cUZtdW82a3prVzJNNVJ1VW8zZnBqT1FFeHZKeHFQc01XOUtOOFk3dWZTQnFrcjlsQlk0ZHJ2dHJSbW03LXhRemRqUW5n?oc=5) |
| Nature | Designing a tumor landscape-modifying vaccine with a unique TLR2/6 agonist for refractory pancreatic cancer | [Source Link](https://news.google.com/rss/articles/CBMiX0FVX3lxTFBCV0R6N2RTYkFHZU1GX09fRkV4WEtSbnJzak1ieXp4VDNFd0pJWnJYNjVyeUpsQlZicU5lSk9mUmNERWRvRmdQb0NRT1Q1N29nNWVGOERpZWpET2R0d2xz?oc=5) |
| Health and Me | New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxNYS01NHdTSFZBQWxNcDBGUlhsXzN6ejRrRWlYYXBZYWE1RnFFbFVKcV9KczVBYzFVdk5qQjJhVUN6dVd0TVA4SmNJLVprN3IzZzJqVUktSzZ6MGJhNkxtY2FPdTlnREItczF0eVF6ZWJaVFpKY1Bjd1lBT0FSWkZWQlJkS1FPMndjcldybHF2bzlEWEg5MmNveC0tVDlERmhkSGhYV2pkYi1KN2gzalJIUjZHam1FN2gxRmZNSm5peGp1UE93YmYyNjRR?oc=5) |
| Investing.com | Elicio to present KRAS vaccine data at cancer conference | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxPOXFsVF9ncV9NVkdhODNFS3A4Q0tERUFJUnBTMzA3dnVJS1g5LTc3NXFzUnh6cE1FMmtId3ctR253YTNtVGxIUjZiOXVldEMtOEVhd3lkU01mZkRXTTExNWJ2eDQxTnU5dmxVTWdocXRnRGxxNWhiampwQXpUdVFuWF9nUzZNMnhVYkxlOUdBaDBpN0VjYVJDTEdKUy1SYk5LSG5jRUFMampaOGZiVXdia2lNaw?oc=5) |
| GlobeNewswire | Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting | [Source Link](https://news.google.com/rss/articles/CBMi8wFBVV95cUxPSjU1VEZUMmU4bFJWSUdKUkJqMnRQMnJpZ0pNOGxPX2pQb0xieDVOa2dicU1jdGU1QW9JTURXVDVvQnBaVW1yN0xlY1h5eENZZS1ac3VybUZ5ZllsZUNtZVVNNGhFekdWZE5BaG1XX0YzWWtOcDZ6QVlpOGRhU2xpWkJURjN6R0V1VjhVTUl4clNtMVltNkN6aDhZNGhMWEZRSEU3WUhNMENYdUlyc3ZiUk1EYmdZQm9Oci1rWjk3bmRmQklodTlhU2NyYldfOUhpVGh6dXhtTHc0bzJtamZoUVVDamUtMXI2bWRiZUVYdHIzd00?oc=5) |
| AllSci | Yonsei team show dual-antigen KRAS/WNT5a vaccine enhances pancreatic cancer immunotherapy | [Source Link](https://news.google.com/rss/articles/CBMigAFBVV95cUxPc0JnQUtpVjdNYUd3dURxOUVYcVIyVUJqLVo2YnlIVFdJQUVIZGR5Tmthd2NZU2NCSlhzdG5qeGl0WWQ2NFFKZk1lWnJVeEFnYWdjSWxtUGFkODJmSWxybjdrdmFSRU9KSm9ydTlhTWRmUk9rNFhCX2txRm8yZ0lPUA?oc=5) |
| Oncodaily | Cosimo Commisso: Personalized KRAS Vaccine Generates Immune Responses in 99% of Patients | [Source Link](https://news.google.com/rss/articles/CBMiYkFVX3lxTFBKel9XTjRxMlJmQTRPdXhNbFNTV1ZHcmVrakZOaDFtZm1kVksxUnZRcXBLaHNyM0lJRml1UEJNOS1IeGhNTE5SY3FUc1N2djRfRnI3aThZUnJ4UnB5NTRjdkhn?oc=5) |
| The Australian | New hope for pancreatic cancer patients with early mRNA vaccine results | [Source Link](https://news.google.com/rss/articles/CBMi6gFBVV95cUxPNl96b2ZGYnBwX2M2T2U0XzlwWmtteUluUVJiSDVnVXFGRVg1MVRFaTBZdHhZRTNiMjRtTUZNM0FGWHRpM2N5cWdiZmptX1gxal9DZ25zZFlMczBRUV9jTTNtNjZwUTJpdWd2QXpTX1h6WFRqQ0FLcDk5cmVaMGxYbE11R21sQ2NweGc4UTdkUHVndmFOREFpa1VPWm44eHdqeDIzaWNJeG80U3BNUHhTcUQ3VzB6R25NU3RDVXF4WnN0ekF5RU16VjVzVzZsaWMzSmptallWQmpHd1NNMENVWkZiWlZleXBabmc?oc=5) |
| The Cancer Letter | Lifesaving vaccines: Using KRAS to harness the power of the immune system | [Source Link](https://news.google.com/rss/articles/CBMiZEFVX3lxTFBqd2lwMEJHbmZvUElwQXFQVzI3T3Z4RzA2M2RMUmtCQU1qdTAybU9zY2lBQm53ZFhXYjVKaEk1c3pPTGFkenJwY2I5dkVHSTV3NXF6b0kyQzR3eEp6Y0N4SWs4RWk?oc=5) |
| Yahoo Finance UK | Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting | [Source Link](https://news.google.com/rss/articles/CBMijAFBVV95cUxOaDVGSUIzbHNtRmVMZUhaUGFUNFpkRlNQdm43bG1iSktSWWZMa3FabFJrLVFsT2RfYnJXc18tZFNMQUlTSTl6TEdFTEJYS1ZIUW9tbVZScVo4bTN2M0o5RjFzLUFRdmtneGFwTS1BbFAwUUdOYVJ3UlBtMXdNTWtwUTdsTzlFTWlDZGVUMg?oc=5) |
| Medical Xpress | Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxQZGppZGdzYk82dlFyOE5tWEU5UTlvdURIS2V5V1o1ckZweGV6ZTdFSldFcDhyNEktOXhtWUN2RHpmajNzQVFQTlZIenBxVkZQa2tyZldGd3NOckNibGp3TXpvYWUwSFN1aFY0WFJUenNHWFJKX2NkNUdlWFh1MTRaSmpvdTB5Wkd3RWc?oc=5) |
| ScienceAlert | New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxPQlQ0VjR5UFE5X2Flb1VMUklnaHdrWmtqZ185QmpqQ0I5WjNxWi16eWZnYjhXVjAzTEZWRW1YWFZJVjg0MGRQc0Ffd0ZoNHdSa2tBV2p1T2FwbTZrQVh4OHhRcDBrN1ZFUnJscGlvNkUxNENTcnVhT2JtbnVDdGdPQWNKLUpvSGljRmtxekJ5a0lJVVc2R2pSZUlpT09OcWVldDBV?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-31/new-pancreatic-cancer-vaccine-sparked-immune-responses-in-99-of-patients*
